Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1998 2
2000 1
2003 1
2004 2
2005 1
2006 1
2012 1
2015 1
2016 3
2017 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group. Hueber W, et al. Among authors: mellgard b. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17. Gut. 2012. PMID: 22595313 Free PMC article. Clinical Trial.
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
Turecek PL, Peck RC, Rangarajan S, Reilly-Stitt C, Laffan MA, Kazmi R, James I, Dushianthan A, Schrenk G, Gritsch H, Ewenstein BM, Mellgard B, Erdlenbruch W, Jain N, Binder NB, Mumford AD. Turecek PL, et al. Among authors: mellgard b. Thromb Res. 2021 May;201:100-112. doi: 10.1016/j.thromres.2021.02.012. Epub 2021 Feb 18. Thromb Res. 2021. PMID: 33662796 Free PMC article.
A comparison of oligonucleotide and cDNA-based microarray systems.
Mah N, Thelin A, Lu T, Nikolaus S, Kühbacher T, Gurbuz Y, Eickhoff H, Klöppel G, Lehrach H, Mellgård B, Costello CM, Schreiber S. Mah N, et al. Among authors: mellgard b. Physiol Genomics. 2004 Feb 13;16(3):361-70. doi: 10.1152/physiolgenomics.00080.2003. Physiol Genomics. 2004. PMID: 14645736
Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
Elstein D, Mellgard B, Dinh Q, Lan L, Qiu Y, Cozma C, Eichler S, Böttcher T, Zimran A. Elstein D, et al. Among authors: mellgard b. Mol Genet Metab. 2017 Sep;122(1-2):113-120. doi: 10.1016/j.ymgme.2017.08.005. Epub 2017 Aug 24. Mol Genet Metab. 2017. PMID: 28851512 Free article. Clinical Trial.
16 results